J 2023

In cellulo and in vivo assays for compound testing against Trypanosoma cruzi

GUERRA-SLOMPO, Eloise Pavao, Gisele Fernanda Assine PICCHI-CONSTANTE, Martin MAREK, Christophe ROMIER, Wolfgang SIPPL et. al.

Basic information

Original name

In cellulo and in vivo assays for compound testing against Trypanosoma cruzi

Authors

GUERRA-SLOMPO, Eloise Pavao, Gisele Fernanda Assine PICCHI-CONSTANTE, Martin MAREK (203 Czech Republic, guarantor, belonging to the institution), Christophe ROMIER, Wolfgang SIPPL and Nilson Ivo Tonin ZANCHIN

Edition

STAR Protocols, United States, Cell Press, 2023, 2666-1667

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

10608 Biochemistry and molecular biology

Country of publisher

Netherlands

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

RIV identification code

RIV/00216224:14310/23:00132246

Organization unit

Faculty of Science

UT WoS

001058390100001

Keywords in English

Cell Biology; Cell-based Assays; High-throughput Screening; Microbiology; Model Organisms

Tags

Tags

International impact, Reviewed
Změněno: 25/1/2024 14:41, Mgr. Marie Šípková, DiS.

Abstract

V originále

Here, we describe a combined in cellulo and in vivo approach to identify com-pounds with higher potential for efficient inhibition of Trypanosoma cruzi. Phase I of in cellulo assays is designed to exclude inactive or toxic compounds, while phase II is designed for accurate IC50, CC50, and selective index (SI) determina-tion. Compounds showing high SI are tested using in vivo infection models in par-allel with benznidazole to assess their efficacy relative to a reference drug used for Chagas disease treatment. For complete details on the use and execution of this protocol, please refer to Marek et al. (2021).1